PMID- 25697576
OWN - NLM
STAT- MEDLINE
DCOM- 20151214
LR  - 20220318
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 239
IP  - 2
DP  - 2015 Apr
TI  - Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin 
      on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation 
      myocardial infarction.
PG  - 439-43
LID - S0021-9150(15)00090-8 [pii]
LID - 10.1016/j.atherosclerosis.2015.02.003 [doi]
AB  - BACKGROUND: The important role of oxidized low density lipoprotein (oxidized-LDL) 
      in preclinic atherosclerosis and pathophysiology of acute coronary syndromes 
      studies have reported. Oxidation of LDL activates many inflammatory and 
      atherogenic pathways and plays a pivotal role in atherosclerosis. Our aim in this 
      study is to compare the effects of 80 mg daily dose of atorvastatin and 20 mg 
      daily dose of rosuvastatin on lipid profiles and the levels of oxidized-LDL and 
      inflammatory markers in ST elevation myocardial infarction (STEMI). METHODS: One 
      hundred and twenty patients with STEMI were enrolled in this study. The patients 
      were randomly assigned to receive atorvastatin (80 mg/day) or rosuvastatin 
      (20 mg/day) by using a ratio of 1:1 after revascularization. The levels of total 
      cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol 
      (HDL-C), LDL-C, apolipoprotein B and apolipoprotein A were compared between 
      groups after 4-week therapy. The values of oxidized-LDL, tumor necrosis factor 
      receptor 1 and 2, Interleukin-6 and hs-CRP were also compared between groups. The 
      Student's t test was used to detect absolute and percent changes between groups, 
      and p < 0.05 was considered as statistically significant for all tests. RESULTS: 
      After treatment in both treatment groups LDL-C, oxidized-LDL, hs-CRP, tumor 
      necrosis factor receptor 1 and 2, Interleukin-6 values significantly decreased 
      according to baseline. The only difference was in HDL-C levels. HDL-C slightly 
      decreased in atorvastatin group while it increased in the rosuvastatin group 
      compared baseline (-1.4 +/- 8.9 mg/dl vs 2.0 +/- 9.4 mg/dl, p = 0.04). CONCLUSION: We 
      reported that both statin treatment regiments have comparable effects on LDL-C, 
      oxidized-LDL and inflammatory markers. Moreover, it was observed that 
      rosuvastatin was more effective in terms of ability to increase HDL-C level. 
      Based on these findings, 20 mg daily dose of rosuvastatin may be an alternative 
      to 80 mg daily dose of atorvastatin in patients with acute coronary syndrome.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Aydin, Meryem Ulku
AU  - Aydin MU
AD  - Denizli Servergazi State Hospital, Department of Cardiology, Denizli, Turkey; 
      Denizli State Hospital, Department of Cardiology, Denizli, Turkey. Electronic 
      address: ulkudr@gmail.com.
FAU - Aygul, Nazif
AU  - Aygul N
AD  - Selcuk University, Selcuklu School of Medicine, Department of Cardiology, Konya, 
      Turkey.
FAU - Altunkeser, Bulent Behlul
AU  - Altunkeser BB
AD  - Selcuk University, Selcuklu School of Medicine, Department of Cardiology, Konya, 
      Turkey.
FAU - Unlu, Ali
AU  - Unlu A
AD  - Selcuk University, Selcuklu School of Medicine, Department of Biochemistry, 
      Konya, Turkey.
FAU - Taner, Alpaslan
AU  - Taner A
AD  - Dr Faruk Sukan Maternity and Children Hospital, Department of Biochemistry, 
      Konya, Turkey.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150207
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Biomarkers)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (IL6 protein, human)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
RN  - 0 (TNFRSF1A protein, human)
RN  - 0 (TNFRSF1B protein, human)
RN  - 0 (oxidized low density lipoprotein)
RN  - 83MVU38M7Q (Rosuvastatin Calcium)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Aged
MH  - Atorvastatin/*administration & dosage
MH  - Biomarkers/blood
MH  - C-Reactive Protein/metabolism
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage
MH  - Inflammation Mediators/*blood
MH  - Interleukin-6/blood
MH  - Lipoproteins, LDL/*blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/diagnosis/*drug therapy
MH  - Receptors, Tumor Necrosis Factor, Type I/blood
MH  - Receptors, Tumor Necrosis Factor, Type II/blood
MH  - Rosuvastatin Calcium/*administration & dosage
MH  - Treatment Outcome
MH  - Turkey
OTO - NOTNLM
OT  - Atorvastatin
OT  - Inflammatory markers
OT  - Lipid parameters
OT  - Oxidized-LDL
OT  - Rosuvastatin
OT  - ST segment elevation myocardial infarction
EDAT- 2015/02/24 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/02/21 06:00
PHST- 2014/11/26 00:00 [received]
PHST- 2015/01/24 00:00 [revised]
PHST- 2015/02/03 00:00 [accepted]
PHST- 2015/02/21 06:00 [entrez]
PHST- 2015/02/24 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S0021-9150(15)00090-8 [pii]
AID - 10.1016/j.atherosclerosis.2015.02.003 [doi]
PST - ppublish
SO  - Atherosclerosis. 2015 Apr;239(2):439-43. doi: 
      10.1016/j.atherosclerosis.2015.02.003. Epub 2015 Feb 7.